^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Excerpt:
......
Trial ID:
Source:
Title:
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
Excerpt:
...Subject agrees to take blood samples for gBRCA mutations, can provide formalin-fixed, paraffin-embedded tumor tissue samples for sBRCA and homologous recombination deficiency(HRD) detection; 10....
Trial ID:
More C2 evidence
Source:
Title:
Niraparib alone or Niraparib and bevacizumab combination in Women with ovarian cancer.
Excerpt:
...Patient consents to perform HRD test.- Patients with known BRCA status: BRCA positive patients must submit the tissue for HRD test, though these patients need not to wait for HRD test results and can be randomized in HRD positive stratum.- If tumor tissue is not sufficient to perform HRD test: these patients shall be randomized in HRD negative stratum as HRD unkown. ...
Trial ID:
Less C2 evidence
Source:
Title:
Phase II OVARIO Study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab
Published date:
03/19/2021
Excerpt:
Overall, 47% of pts were HRd, including HRd-BRCA mutated and HRd-BRCA wild-type.The niraparib starting dose was 200 mg in 78% of pts . At 6 and 12 months, PFS rates were 90% and 75%, respectively....Safety of the niraparib + bevacizumab combination was consistent with the known side effects of each drug as monotherapy, and the preliminary data suggest that the combination is efficacious.
Trial ID:
